Matches in Wikidata for { <http://www.wikidata.org/entity/Q65362390> ?p ?o ?g. }
Showing items 1 to 53 of
53
with 100 items per page.
- Q65362390 description "clinical trial" @default.
- Q65362390 description "ensayu clínicu" @default.
- Q65362390 description "klinisch onderzoek" @default.
- Q65362390 description "клінічне випробування" @default.
- Q65362390 name "A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)" @default.
- Q65362390 name "A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma" @default.
- Q65362390 type Item @default.
- Q65362390 label "A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)" @default.
- Q65362390 label "A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma" @default.
- Q65362390 prefLabel "A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)" @default.
- Q65362390 prefLabel "A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma" @default.
- Q65362390 P1050 Q65362390-8203FE00-C9B2-4EE3-9F1A-1C5E2A8BF497 @default.
- Q65362390 P1132 Q65362390-6F0458FA-D30F-414C-B579-2BDD9099F11C @default.
- Q65362390 P1476 Q65362390-B21E4CEB-6551-446D-8939-721159D2E7B4 @default.
- Q65362390 P17 Q65362390-05AF63F8-6DC8-4895-B5C3-2082A8B645C1 @default.
- Q65362390 P17 Q65362390-523E2D75-7033-4BA0-BBDC-A3DEAB84A5E8 @default.
- Q65362390 P17 Q65362390-54DE555B-220B-4AF5-895C-AF1AD828047F @default.
- Q65362390 P17 Q65362390-5A70E84E-672B-46D8-8FF3-9E6A6EC88AB1 @default.
- Q65362390 P17 Q65362390-6C2FBF8C-25F2-47A0-AB9E-BC5F978010A1 @default.
- Q65362390 P17 Q65362390-6EAA0281-D117-4A1F-8AD8-4808B730528C @default.
- Q65362390 P17 Q65362390-92311BFC-615F-4E06-8498-22676A17522F @default.
- Q65362390 P17 Q65362390-BDDF2133-D137-4572-96FF-6E147152E544 @default.
- Q65362390 P17 Q65362390-C75A5EBC-2465-4FC6-BBC3-13773B8FA314 @default.
- Q65362390 P17 Q65362390-CBEB4B42-E0BE-448B-8EB4-3F03C28CA917 @default.
- Q65362390 P17 Q65362390-D5770179-FB9B-469A-988C-40F1B84B2ECA @default.
- Q65362390 P2899 Q65362390-4F0FCF2A-43F0-4DFB-A3C5-8FC79B467B0D @default.
- Q65362390 P3098 Q65362390-8FD4FC46-AA17-49AD-A654-CCCA8BB35EAF @default.
- Q65362390 P31 Q65362390-FFC05658-A31B-47B0-B2A5-E938CBD4D070 @default.
- Q65362390 P580 Q65362390-2809B240-9A63-4B4A-9E0D-12C331A7B143 @default.
- Q65362390 P582 Q65362390-7D0D17EC-4C36-4068-9D1D-36E4CFFCBCE3 @default.
- Q65362390 P6099 Q65362390-527E1689-08EB-4148-883D-7223132EE1D6 @default.
- Q65362390 P8363 Q65362390-2D17B975-9DCA-4AED-AAD7-30A05675CA85 @default.
- Q65362390 P1050 Q208414 @default.
- Q65362390 P1132 "+129" @default.
- Q65362390 P1476 "A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)" @default.
- Q65362390 P17 Q142 @default.
- Q65362390 P17 Q145 @default.
- Q65362390 P17 Q16 @default.
- Q65362390 P17 Q184 @default.
- Q65362390 P17 Q219 @default.
- Q65362390 P17 Q230 @default.
- Q65362390 P17 Q28 @default.
- Q65362390 P17 Q29 @default.
- Q65362390 P17 Q30 @default.
- Q65362390 P17 Q31 @default.
- Q65362390 P17 Q38 @default.
- Q65362390 P2899 "+18" @default.
- Q65362390 P3098 "NCT01882803" @default.
- Q65362390 P31 Q30612 @default.
- Q65362390 P580 "2013-05-01T00:00:00Z" @default.
- Q65362390 P582 "2016-05-01T00:00:00Z" @default.
- Q65362390 P6099 Q42824440 @default.
- Q65362390 P8363 Q78089383 @default.